Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791528 | 0.95 | LPL (0.58) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL3784543 | 0.86 | LPL (0.50) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL3786679 | 0.84 | LPL (0.48) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL10136924 | 0.84 | LPL (0.49) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL10269834 | 0.84 | LPL (0.48) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL12247400 | 0.84 | LPL (0.48) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL23958100 | 0.81 | LPL (0.45) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL14665438 | 0.81 | ENPP2 (0.48) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL12327391 | 0.80 | ENPP2 (0.47) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL17677146 | 0.80 | MGLL (0.47) | LPLLIPGENPP2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119780-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-11136565-B2 | Modified archaeal family B polymerases | Singular Genomics Systems, Inc. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | LPL 2816/4885LIPG 3273/4885ENPP2 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.